tetano
Editor, Senior Moderator
Brain Behav Immun
. 2020 Jun 16;S0889-1591(20)31008-4.
doi: 10.1016/j.bbi.2020.06.020. Online ahead of print.
Spectrum of Neuropsychiatric Manifestations in COVID-19
Krishna Nalleballe[SUP] 1 [/SUP], Sanjeeva Reddy Onteddu[SUP] 1 [/SUP], Rohan Sharma[SUP] 1 [/SUP], Vasuki Dandu[SUP] 2 [/SUP], Aliza Brown[SUP] 1 [/SUP], Madhu Jasti[SUP] 3 [/SUP], Sisira Yadala[SUP] 1 [/SUP], Karthika Veerapaneni[SUP] 1 [/SUP], Suman Siddamreddy[SUP] 2 [/SUP], Akshay Avula[SUP] 4 [/SUP], Nidhi Kapoor[SUP] 1 [/SUP], Kamran Mudassar[SUP] 5 [/SUP], Sukanthi Kovvuru[SUP] 1 [/SUP]
Affiliations
Abstract
Corona Virus Disease 2019 (COVID-19) emerged in December 2019 from Wuhan, China. It typically presents with mild upper respiratory tract infection symptoms and may have life threatening complications, including acute respiratory distress syndrome, acute stroke, myocardial infarction, kidney failure, shock, and even death. Coronavirus infections are known to have neuroinvasive potential with consequent neuropsychiatric manifestations. We analyzed COVID-19 adult patients in the TriNetX database, which is a global health collaborative clinical research platform collecting real-time electronic medical records data from a network of health care organizations (HCOs) from January 20, 2020 to June 10[SUP]th[/SUP], 2020. 40,469 patients were diagnosed with COVID-19 among whom 9086 (22.5%) patients had neuropsychiatric manifestations. The most common neurologic manifestations included headache (3.7%) and sleep disorders (3.4%), Encephalopathy (2.3%), Stroke and transient ischemic attack (TIA) (1.0%) and 0.6% had seizures. Most common psychiatric manifestations included anxiety and other related disorders (4.6%), mood disorders (3.8%), while 0.2% patients had suicidal ideation. Early recognition and prompt management of neuropsychiatric manifestations in these patients have a potential to decrease overall morbidity and mortality.
. 2020 Jun 16;S0889-1591(20)31008-4.
doi: 10.1016/j.bbi.2020.06.020. Online ahead of print.
Spectrum of Neuropsychiatric Manifestations in COVID-19
Krishna Nalleballe[SUP] 1 [/SUP], Sanjeeva Reddy Onteddu[SUP] 1 [/SUP], Rohan Sharma[SUP] 1 [/SUP], Vasuki Dandu[SUP] 2 [/SUP], Aliza Brown[SUP] 1 [/SUP], Madhu Jasti[SUP] 3 [/SUP], Sisira Yadala[SUP] 1 [/SUP], Karthika Veerapaneni[SUP] 1 [/SUP], Suman Siddamreddy[SUP] 2 [/SUP], Akshay Avula[SUP] 4 [/SUP], Nidhi Kapoor[SUP] 1 [/SUP], Kamran Mudassar[SUP] 5 [/SUP], Sukanthi Kovvuru[SUP] 1 [/SUP]
Affiliations
- PMID: 32561222
- DOI: 10.1016/j.bbi.2020.06.020
Abstract
Corona Virus Disease 2019 (COVID-19) emerged in December 2019 from Wuhan, China. It typically presents with mild upper respiratory tract infection symptoms and may have life threatening complications, including acute respiratory distress syndrome, acute stroke, myocardial infarction, kidney failure, shock, and even death. Coronavirus infections are known to have neuroinvasive potential with consequent neuropsychiatric manifestations. We analyzed COVID-19 adult patients in the TriNetX database, which is a global health collaborative clinical research platform collecting real-time electronic medical records data from a network of health care organizations (HCOs) from January 20, 2020 to June 10[SUP]th[/SUP], 2020. 40,469 patients were diagnosed with COVID-19 among whom 9086 (22.5%) patients had neuropsychiatric manifestations. The most common neurologic manifestations included headache (3.7%) and sleep disorders (3.4%), Encephalopathy (2.3%), Stroke and transient ischemic attack (TIA) (1.0%) and 0.6% had seizures. Most common psychiatric manifestations included anxiety and other related disorders (4.6%), mood disorders (3.8%), while 0.2% patients had suicidal ideation. Early recognition and prompt management of neuropsychiatric manifestations in these patients have a potential to decrease overall morbidity and mortality.